We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · September 12, 2021

Botulinum Neurotoxin Use in a Tertiary Oculoplastic Centre

Eye (London, England)


Additional Info

Eye (London, England)
Prevalence, indications and demographic characteristics of Botulinum neurotoxin use in a tertiary oculoplastic centre
Eye (Lond) 2021 Jun 28;[EPub Ahead of Print], I De Silva, C Lim, M Thomas, A Berry-Brincat, R Sampath, J Burns

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading